Compare AbCellera Biologics Inc (ABCL) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.49 (market cap $20.14M). The key difference: AbCellera Biologics Inc is far larger — about 116.7× Avalanche Treasury Corporation Class A Common Stock's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ABCL | AVAT | |
|---|---|---|
Market Cap | $2.35B | $20.14M |
Sector | Health | Financials |
52-Week High | $8.12 | $10.75 |
52-Week Low | $2.78 | $0.51 |
Enterprise Value | $1.99B | $20.14M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
AVAT trades at $0.5114, down 3.22% today, with a bearish technical signal from moving averages and a neutral oscillator reading. The company reported a net income of $8.28 million for 2025 but shows negative operating cash flow of -$930,710. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is cautious due to weak cash flow and bearish technicals, though low P/E and P/B ratios may appeal to value investors. Key risks include operational sustainability and market sentiment shifts. Analyst consensus is not yet established post-listing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
